JP2005523268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523268A5 JP2005523268A5 JP2003565457A JP2003565457A JP2005523268A5 JP 2005523268 A5 JP2005523268 A5 JP 2005523268A5 JP 2003565457 A JP2003565457 A JP 2003565457A JP 2003565457 A JP2003565457 A JP 2003565457A JP 2005523268 A5 JP2005523268 A5 JP 2005523268A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- phenyl
- solvate
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 239000000048 adrenergic agonist Substances 0.000 claims 8
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- -1 C (O) NR 18 R 19 Chemical group 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000000241 respiratory effect Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- XOMKGHYLXJYSSU-YFWFAHHUSA-N s-(fluoromethyl) (8s,9s,10r,13s,14s,17s)-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydro-3h-cyclopenta[a]phenanthrene-17-carbothioate Chemical compound C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)SCF)[C@@H]4[C@@H]3CCC2=C1 XOMKGHYLXJYSSU-YFWFAHHUSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000000273 veterinary drug Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/066,961 US6537983B1 (en) | 2001-04-07 | 2002-02-04 | Anti-inflammatory androstane derivatives |
| PCT/GB2003/000485 WO2003066033A1 (en) | 2002-02-04 | 2003-02-04 | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523268A JP2005523268A (ja) | 2005-08-04 |
| JP2005523268A5 true JP2005523268A5 (enExample) | 2006-01-05 |
Family
ID=27732220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565457A Withdrawn JP2005523268A (ja) | 2002-02-04 | 2003-02-04 | グルココルチコイドおよびβ２−アドレナリン受容体アゴニストを含む吸入用製剤 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1471895B2 (enExample) |
| JP (1) | JP2005523268A (enExample) |
| AT (1) | ATE396716T1 (enExample) |
| AU (1) | AU2003205855A1 (enExample) |
| DE (1) | DE60321311D1 (enExample) |
| ES (1) | ES2305438T5 (enExample) |
| WO (1) | WO2003066033A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| AU2011315315B2 (en) | 2010-10-12 | 2016-08-18 | Cipla Limited | Pharmaceutical composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL95590A (en) † | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| GB9903759D0 (en) † | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| CA2417826A1 (en) * | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002070490A1 (en) * | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| EP1370521B1 (en) * | 2001-03-22 | 2007-12-19 | Glaxo Group Limited | Formanilide derivatives as beta2-adrenoreceptor agonists |
| UA77656C2 (en) † | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
-
2003
- 2003-02-04 EP EP03702732A patent/EP1471895B2/en not_active Expired - Lifetime
- 2003-02-04 AU AU2003205855A patent/AU2003205855A1/en not_active Abandoned
- 2003-02-04 AT AT03702732T patent/ATE396716T1/de not_active IP Right Cessation
- 2003-02-04 DE DE60321311T patent/DE60321311D1/de not_active Expired - Lifetime
- 2003-02-04 ES ES03702732T patent/ES2305438T5/es not_active Expired - Lifetime
- 2003-02-04 JP JP2003565457A patent/JP2005523268A/ja not_active Withdrawn
- 2003-02-04 WO PCT/GB2003/000485 patent/WO2003066033A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527496A5 (enExample) | ||
| JP4801042B2 (ja) | パーキンソンプラス症候群の治療及び予防のためのロチゴチンの使用 | |
| JP5042042B2 (ja) | ２−アミノ−１，３−プロパンジオール誘導体を有効成分とする炎症性腸疾患治療剤又は炎症性腸疾患の治療方法 | |
| RU2001126347A (ru) | Композиции, включающие формотерол и фуроат мометасона, предназначенные для лечения астмы | |
| RU2001123923A (ru) | Композиции, включающие формотерол и соль тиотропия | |
| JP2006502172A (ja) | 抗炎症性または抗アレルギー性アンドロスタン複合体 | |
| RU2013119938A (ru) | Фармацевтическая композиция | |
| PT100144B (pt) | Composicoes farmaceuticas contendo rapamicina e metodo para o tratamento de inflamacoes pulmonares utilizando-as | |
| KR20020059416A (ko) | 프로게스테론 또는 이의 유사체들을 유효성분으로함유하는 염증 치료용 약학적 조성물 | |
| RU2010108640A (ru) | Новая комбинация терапевтических агентов | |
| JP2004521950A5 (enExample) | ||
| RU2006132195A (ru) | Комбинация агонистов бета-2 адренорецептора, бензотиазол-2-онов и кортикостероидов, предназначенная для лечения респираторных заболеваний | |
| JP2005537278A (ja) | 抗炎症性または抗アレルギー性アンドロスタン複合体 | |
| JP2008509119A (ja) | 慢性呼吸疾患の治療薬 | |
| AU2015261103A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD | |
| CN106232588B (zh) | 环己烯基化合物、包含其的组合物及其用途 | |
| JP2007505829A5 (enExample) | ||
| WO2014096115A1 (en) | Ciclesonide for the treatment of airway disease in horses | |
| JP2009544690A5 (enExample) | ||
| CA2538419A1 (en) | Use of ciclesonide for the treatment of respiratory diseases | |
| JP2005523268A5 (enExample) | ||
| KR20180118667A (ko) | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 | |
| US20140031324A1 (en) | Compound composition for inhalation used for treating asthma | |
| CN101805285A (zh) | 含烟酸姜黄素酯衍生物及其制造方法和用途 | |
| WO2009071990A2 (en) | No-donating cordicosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties |